Claims Covering Use of Estrogens, Including TRIMESTA, in Combination With Popular Immunotherapies to Treat Multiple Sclerosis.

Pipex Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has received a notice of allowance from the US Patent Office for claims to a patent which covers the use of estrogens in combination with other FDA-approved multiple sclerosis therapies for the treatment of autoimmune diseases.

Pipex's product candidate TRIMESTA (oral, once-daily estriol), which is covered by this notice of allowance, is currently in a Phase III multi-center, placebo-controlled clinical trial in combination with Copaxone for treatment of multiple sclerosis that is being funded by a $5 million grant from the National Multiple Sclerosis Society, its largest single grant ever for a clinical trial.....................

For the full report please go to MSRC: MS Research News : Drugs : Trimesta (Oral Estriol) - http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1878